Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
| Descriptor ID |
D047428
|
| MeSH Number(s) |
D27.505.519.389.755
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 3 | 4 |
| 2007 | 4 | 2 | 6 |
| 2008 | 3 | 14 | 17 |
| 2009 | 4 | 3 | 7 |
| 2010 | 7 | 9 | 16 |
| 2011 | 9 | 6 | 15 |
| 2012 | 6 | 9 | 15 |
| 2013 | 6 | 12 | 18 |
| 2014 | 16 | 6 | 22 |
| 2015 | 15 | 5 | 20 |
| 2016 | 18 | 10 | 28 |
| 2017 | 12 | 9 | 21 |
| 2018 | 19 | 5 | 24 |
| 2019 | 11 | 12 | 23 |
| 2020 | 14 | 12 | 26 |
| 2021 | 19 | 12 | 31 |
| 2022 | 2 | 15 | 17 |
| 2023 | 4 | 11 | 15 |
| 2024 | 14 | 5 | 19 |
| 2025 | 6 | 6 | 12 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway Deficits. Mol Cancer Ther. 2025 Jun 04; 24(6):859-869.
-
Comprehensive evaluation of phosphoproteomic-based kinase activity inference. Nat Commun. 2025 May 22; 16(1):4771.
-
ESR1 Y537S and D538G Mutations Drive Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res. 2025 May 01; 31(9):1667-1675.
-
Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2025 Jul; 212(1):71-78.
-
Early nintedanib deployment in COVID-19 interstitial lung disease (ENDCOV-I): study protocol of a randomised, double-blind, placebo-controlled trial. BMJ Open Respir Res. 2025 Apr 10; 12(1).
-
Current and emerging treatment perspectives for adults with Waldenstr?m macroglobulinemia. Expert Rev Anticancer Ther. 2025 May; 25(5):485-497.
-
Pediatric relapsed/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug era. Blood Adv. 2025 Mar 25; 9(6):1356-1365.
-
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations. Blood Cancer J. 2025 Mar 15; 15(1):40.
-
Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma. J Clin Endocrinol Metab. 2025 Feb 18; 110(3):e600-e606.
-
Zanubrutinib for the treatment of Bing-Neel syndrome. Br J Haematol. 2025 Apr; 206(4):1136-1140.